He previously worked at 3M for 17 years, leading R&D efforts in both corporate innovation and business segment roles, including an international assignment based in South Korea.

Gajewski joined Avient in July 2013 from AkzoNobel/PPG and has since taken on multiple roles with increasing responsibility within the Human Resources function, including HR Director for Avient’s Color, Additives & Inks business segment, and an international assignment with responsibility for the EMEA and India regions.

He previously worked at 3M for 17 years, leading R&D efforts in both corporate innovation and business segment roles, including an international assignment based in South Korea.

THE CHALLENGE A global business equipment manufacturer decided to develop a premium line of computer mouse products that offered improved ergonomics and soft-touch qualities. The business goal was to boost penetration in this market category by creating a new higher- performing mouse that offered added comfort and features aimed at an enhanced user experience.

They are based on management’s expectations that involve a number of business risks and uncertainties, any of which could cause actual results to differ materially from those expressed in or implied by the forward-looking statements. Avient’s chief operating decision maker uses these financial measures to monitor and evaluate the ongoing performance of Avient and each business segment and to allocate resources. Management believes this provides comparability of the performance of the combined businesses.

Avient's chief operating decision maker uses these financial measures to monitor and evaluate the ongoing performance of the company and each business segment and to allocate resources. They are based on management's expectations that involve a number of business risks and uncertainties, any of which could cause actual results to differ materially from those expressed in or implied by the forward-looking statements. Factors that could cause actual results to differ materially from those implied by these forward-looking statements include, but are not limited to: disruptions, uncertainty or volatility in the credit markets that could adversely impact the availability of credit already arranged and the availability and cost of credit in the future; the effect on foreign operations of currency fluctuations, tariffs and other political, economic and regulatory risks; changes in laws and regulations regarding plastics in jurisdictions where we conduct business; fluctuations in raw material prices, quality and supply, and in energy prices and supply; production outages or material costs associated with scheduled or unscheduled maintenance programs; unanticipated developments that could occur with respect to contingencies such as litigation and environmental matters; our ability to achieve strategic objectives and successfully integrate acquisitions, including Avient Protective Materials; an inability to raise or sustain prices for products or services; our ability to pay regular quarterly cash dividends, including at the increased rate, and the amounts and timing of any future dividends; information systems failures and cyberattacks; amounts for cash and non-cash charges related to restructuring plans that may differ from original estimates, including because of timing changes associated with the underlying actions; and other factors affecting our business beyond our control, including without limitation, changes in the general economy, changes in interest rates, changes in the rate of inflation and any recessionary conditions.

They are based on management’s expectations that involve a number of business risks and uncertainties, any of which could cause actual results to differ materially from those expressed in or implied by the forward-looking statements. Avient’s chief operating decision maker uses these financial measures to monitor and evaluate the ongoing performance of Avient and each business segment and to allocate resources. Management believes this provides comparability of the performance of the combined businesses.

Testing by the manufacturer of the material produced in Asia showed that it per formed identically to that made in the United States.

EDGETEK™ POLYETHERETHERKETONE (PEEK) HIGH PERFORMING MELT-PROCESSABLE POLYMER PRODUCT SELECTION GUIDE Edgetek™ Polyetheretherketone (PEEK) HIGH PERFORMING MELT-PROCESSABLE POLYMER PROPERTY CONDITIONS TEST METHOD UNITS EDGETEK ™ ET9800-0001 EM EDGETEK™ ET9800-0002 RS EDGETEK™ ET9800-0003 RS EDGETEK™ ET9800-0004 RS EC LUBRIONE™ LB9800-0001 AR PHYSICAL Mold Shrinkage - Transverse – ASTM D955 in/in 0.014 0.010 0.011 0.009 0.014 MECHANICAL Tensile Strength - Yield – ASTM D638 PSI 14425 15640 23680 36500 19700 Tensile Elongation - Yield – ASTM D638 % 5.4 3.0 2.2 1.5 0.2 Tensile Elongation - Break – ASTM D638 % 19.5 3.1 2.2 1.5 1.9 Tensile Modulus – ASTM D638 PSI 555150 827700 1591300 5301000 2285600 Flexural Modulus – ASTM D790 PSI 529300 690700 1418300 3084300 1443400 Flexural Strength – ASTM D790 PSI 23500 27300 36000 52100 30300 IMPACT Izod, Notched – ASTM D256 ft-lbs/in 1.0 0.7 1.1 1.3 0.6 Izod, Unnotched – ASTM D256 ft-lbs/in N.B. 13.1 15.3 13.8 5.0 THERMAL Melting Point – – °C 343 343 343 343 343 Glass Transition (DSC) – – °C 143 143 143 143 143 Heat Deflection Temp 264 psi, Unannealed ASTM D648 °C 151 178 320 325 > 300 CLTE, Flow Direction 23°C to 140°C ASTM E831 cm/cm/°C 4.0E-05 5.5E-05 2.2E-05 7.0E-06 1.9E-05 CLTE, Flow Direction 140°C to 250°C ASTM E831 cm/cm/°C 9.7E-05 7.8E-05 2.3E-05 6.5E-06 2.2E-05 Polyetheretherketone (PEEK) is widely considered to be one of the highest performing melt-processable polymers in the industry.

Avient products have not been designed for nor are they promoted or intended for use in: (a) medical devices categorized by either the United States Food and Drug Administration (FDA) or the International Standards Organization (ISO) as an “implant” device; or “Permanent” as defined under US Pharmacopoeia (USP) or ISO standards; or (b) active implantable medical devices as defined in EU Directive 90/385/EEC as amended; or (c) medical devices for “Long Term” use as defined in EU Directive 93/42/EEC as amended.